NCT00262041View on ClinicalTrials.gov

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

524

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Prevention of Meningococcal Disease
Interventions
BIOLOGICAL

MenACWY-CRM conjugate vaccine, adjuvanted

BIOLOGICAL

MenACWY-CRM conjugate vaccine, unadjuvanted

BIOLOGICAL

MenACWY polysaccharide vaccine

Trial Locations (3)

15241

Pittsburgh

55905

Rochester

98101

Seattle

Sponsors

Lead Sponsor

Novartis Vaccines

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Novartis Vaccines

INDUSTRY